Please ensure Javascript is enabled for purposes of website accessibility

Clover Health Is Down Big. Is It a Buy?

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After a short-seller report, the Medicare company has taken a hit. Is it worth a closer look?

Chamath Palihapitiya has taken three companies public through his special-purpose acquisition companies (SPACs) and has announced a fourth in recent months. Since their merger announcements, all are handily outperforming the market but one -- Clover Health (CLOV 2.21%). In this Fool Live video clip, recorded on March 15, Fool.com contributors Matt Frankel, CFP, Brian Withers, and Dan Caplinger discuss why Clover Health has performed so poorly and whether the stock is worth a look for long-term investors now.

Matt Frankel: This is the one that everyone's been asking. At least, when Dan and I do SPAC shows, half of the questions are about Clover Health in the chat. It's fun that we're going to talk about Clover Health. They're a Medicare Advantage company, but they're also primarily a technology company. They have something called Clover Assistant that really aims to make the Medicare process better, and optimize the claims, and physician relationships and things like that. The stock is down 40% year-to-date, which a lot of investors are undeniably not too happy about. There was a big short seller report that I'm sure, either Dan or Brian can weigh in on. Clover Health, the business itself is doing pretty well. The revenue grew 46% in 2020. They're losing money, but with growth like that, they're not that concerned. They were the third IPO. Their ticker symbol is C-L-O-V and this was formerly I-P-O-C when it was in SPAC form. What do you guys think about Clover Health?

Brian Withers: Go ahead, Dan.

Dan Caplinger: Brian, you want to go?

Withers: No, go.

Caplinger: I had a chance to talk with CEO, Vivek Garipalli, when this was first getting announced. He would tell you that this business is highly misunderstood. Like you were saying Matt, a lot of people just look at this as an insurance company. When the deal was announced, pretty unusual, the SPAC had kind of run up, and then the SPAC actually pulled back when the announcement was made. I think a lot of people were hoping that Chamath would pick a different tech company versus something with this sort of healthcare angle to it. The short selling report is focused on uncertainty about the past experience that Garipalli has. But he's a healthcare professional, he's done healthcare stuff for a long time, he knows how the business works. I think you're going to see this evolve over time to be a different looking business than what a lot of people see at first sight.

Withers: Yeah, I absolutely like their approach. Electronic health records, plus insurance company, plus AI and machine learning tools to help doctors. It gets better and better with more and more data and more and more patients. The runway is huge. I like their focus on Medicare and older humans who have multiple kind of situations, and they have to see multiple physicians and specialists to get things done. I like that it's got revenue.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Clover Health Investments, Corp. Stock Quote
Clover Health Investments, Corp.
CLOV
$2.78 (2.21%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
327%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.